Cytosolic calcium levels in spermatozoa are modulated differently in healthy subjects and patients with varicocele

OBJECTIVE: To study parameters connected to fertility in the semen of patients with varicocele. DESIGN: We examine the ability of spermatozoa obtained from patients with varicocele to respond with an increase of cytosolic Ca2+ ([Ca2+]i) to some stimuli that are connected with spermatozoa activation. SETTING: An academic research environment. PATIENT(S): Ten healthy volunteer donors and 10 patients affected by II or III grade left varicocele. INTERVENTION(S): Spermatozoa and prostasomes (vesicles of prostatic origin obtained from semen) were prepared according to standard procedures. Spermatozoa were stimulated with 1 microM P. The [Ca2+]i was evaluated with the FURA II method. MAIN OUTCOME MEASURE(S): The level of [Ca2+]i. RESULT(S): In resting cells, the level of [Ca2+]i was 120 +/-15 nmol/L (10 determinations). This value increases by > or =100 nmol/L upon stimulation with P. No difference was observed between spermatozoa obtained from healthy donors or from patients with varicocele. S-nitrosocysteine, a nitric oxide donor, and the fusion between spermatozoa and prostasomes increased the effect of P on [Ca2+]i in control spermatozoa but not in spermatozoa obtained from patients with varicocele. CONCLUSION(S): Different responsiveness of varicocele patients' spermatozoa to S-nitrosocysteine and/or to fusion with prostasomes may be among the possible causes of reduced fertility

Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group

The following position paper summarizes the recommendations for early clinical trials and ongoing basic research in the field of mesenchymal stem cell-induced solid organ graft acceptance-agreed upon on the first meeting of the Mesenchymal Stem Cells In Solid Organ Transplantation (MISOT) study group in late 2008

Western Star, 1918-12-11

The Western Star began publication on Newfoundland's west coast on 4 April 1900, appearing weekly with brief semiweekly periods up to 1952, when it became a daily. As of 17 April 2019 it continues as a free weekly community paper

Analisi fitobatteriologiche, necessarie per i servizi fitosanitari regionali

The Legislative Decree n.214 dated 19-9-2005 introduced in Italy the Council Directive 2000/29/CE, as amended by the Council Directive 2002/89/CE. The aforesaid Decree enforced protective measures against the introduction and spread into the Community of organisms harmful to plants/plants products. In the annexes of the Decree, there are 20 phytopathogenic bacteria. The key measures foreseen in the Decree are strengthened plant health checks, carried out by the regional Plant Health Services (SFR) at the place of production and on imported/exported plants/plant products. In this respect, laboratory analyses are essential for the detection of latent infections. Currently, the analyses are carried out in laboratories belonging to SFR or, under the supervision of each SFR, in private or public laboratories. The Decree 214/2005 lays down a national laboratory network (art.53) to support SFR in performing their analyses. The network operates under the supervision of a central Phytosanitary Committee (art.52). In 2006, a special inquiry showed that SFR are characterised by different needs as they perform different bacteriological analyses for the crops grown in their areas and for the checks of other materials imported through the relevant points of entry. Nevertheless three quarantine bacteria resulted to be of common interest. The national laboratory network, laid down by the Decree 214/2005, should take into account the demand for analyses expressed by the SFR, that have already provided useful data regarding their bacteriological needs. This national laboratory network could provide the SFR with an effective support also in the control of regulated non quarantine pests

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT) : an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT process and meeting FACT-JACIE accreditation requirements relating to 1-year survival outcomes. Informed by previous experience from Europe, North America and Australasia, the Clinical Outcomes Group (COG) established criteria for patient and Center selection, and a set of key clinical variables within a dedicated statistical model adapted to the capabilities of the EBMT Registry. The first phase of the project was launched in 2019 to test the acceptability of the benchmarking model through assessment of Centers' performance for 1-year data completeness and survival outcomes of autologous and allogeneic HSCT covering 2013-2016. A second phase was delivered in July 2021 covering 2015-2019 and including survival outcomes. Reports of individual Center performance were shared directly with local principal investigators and their responses were assimilated. The experience thus far has supported the feasibility, acceptability and reliability of the system as well as identifying its limitations. We provide a summary of experience and learning so far in this 'work in progress', as well as highlighting future challenges of delivering a modern, robust, data-complete, risk-adapted benchmarking program across new EBMT Registry systems

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT process and meeting FACT-JACIE accreditation requirements relating to 1-year survival outcomes. Informed by previous experience from Europe, North America and Australasia, the Clinical Outcomes Group (COG) established criteria for patient and Center selection, and a set of key clinical variables within a dedicated statistical model adapted to the capabilities of the EBMT Registry. The first phase of the project was launched in 2019 to test the acceptability of the benchmarking model through assessment of Centers’ performance for 1-year data completeness and survival outcomes of autologous and allogeneic HSCT covering 2013–2016. A second phase was delivered in July 2021 covering 2015–2019 and including survival outcomes. Reports of individual Center performance were shared directly with local principal investigators and their responses were assimilated. The experience thus far has supported the feasibility, acceptability and reliability of the system as well as identifying its limitations. We provide a summary of experience and learning so far in this ‘work in progress’, as well as highlighting future challenges of delivering a modern, robust, data-complete, risk-adapted benchmarking program across new EBMT Registry systems